Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder.

ABSTRACT: Major depressive disorder (MDD) contributes to a significant worldwide disease burden, expected to be second only to heart disease by 2050. However, accurate diagnosis has been a historical weakness in clinical psychiatry. As a result, there is a demand for diagnostic modalities with greater objectivity that could improve on current psychiatric practice that relies mainly on self-reporting of symptoms and clinical interviews. Over the past two decades, literature on a growing number of putative biomarkers for MDD increasingly suggests that MDD patients have significantly different biological profiles compared to healthy controls. However, difficulty in elucidating their exact relationships within depression pathology renders individual markers inconsistent diagnostic tools. Consequently, f

SUBMITTER: Young JJ 

PROVIDER: S-EPMC4843170 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature